How Treatment May Help


RYDAPT® (midostaurin) capsules is given, along with chemotherapy, to adults with newly diagnosed acute myeloid leukemia (AML) who test positive for the FLT3 mutation.

RYDAPT has been proven to help patients with newly diagnosed FLT3+ AML live longer

In a clinical trial of adult patients with newly diagnosed FLT3+ AML:

RYDAPT clinical trial design RYDAPT clinical trial design RYDAPT clinical trial design

What are the potential benefits of taking RYDAPT?

Patients who received treatment with RYDAPT plus chemotherapy lived longer than patients receiving chemotherapy alone.

In the clinical trial, there was a 23% reduction in the risk of death compared with standard-of-care chemotherapy alone. A specific median overall survival (the time point at which half the patients were still alive) could not be reliably estimated.


More patients taking RYDAPT plus chemotherapy (59%) received stem cell transplant (SCT) than patients taking chemotherapy alone (55%). At the time of SCT, study medication was stopped in these patients.


In addition, patients who received RYDAPT with chemotherapy in the trial went longer without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia, or death) than patients who received chemotherapy alone: median 8.2 months vs 3 months.